T he balance between pro-and anti-cell death signals is critical for tissue homeostasis and the health of organisms [1] [2] [3] [4] . Necroptosis is programmed necrosis or inflammatory cell death that links the inflammatory response with tumour initiation and progression [5] [6] [7] [8] [9] [10] [11] [12] . Receptor-interacting serine/threonineprotein kinase 3 (RIPK3) is the main initiator of necroptosis and its phosphorylation promotes the formation of a functional complex (the necrosome) with RIPK1 7, 11, [13] [14] [15] . Mixed lineage kinase domainlike (MLKL), the crucial mediator of necroptosis, is then activated at the necrosome and triggers an inflammatory reaction 11, 14 . However, how the necrosome is negatively regulated remains largely unknown. Therefore, the study of the negative regulation of necroptosis and its role in maintaining an optimal immune response is of critical importance.
T he balance between pro-and anti-cell death signals is critical for tissue homeostasis and the health of organisms [1] [2] [3] [4] . Necroptosis is programmed necrosis or inflammatory cell death that links the inflammatory response with tumour initiation and progression [5] [6] [7] [8] [9] [10] [11] [12] . Receptor-interacting serine/threonineprotein kinase 3 (RIPK3) is the main initiator of necroptosis and its phosphorylation promotes the formation of a functional complex (the necrosome) with RIPK1 7, 11, [13] [14] [15] . Mixed lineage kinase domainlike (MLKL), the crucial mediator of necroptosis, is then activated at the necrosome and triggers an inflammatory reaction 11, 14 . However, how the necrosome is negatively regulated remains largely unknown. Therefore, the study of the negative regulation of necroptosis and its role in maintaining an optimal immune response is of critical importance.
AMP-activated protein kinase (AMPK) is a highly conserved serine/threonine protein kinase that is activated under conditions of depleted cellular ATP and elevated AMP levels, such as glucose deprivation 16, 17 . The function of AMPK is to monitor and maintain energy homeostasis. Previous studies, including preclinical studies, have shown that AMPK has anti-inflammatory or antitumour functions. Unlike other cell death signals, necroptosis is closely related to the depletion of intracellular ATP. There might therefore be an unexplored link between AMPK and necroptosis.
Loss of the E3 ubiquitin ligase function of Parkin is common in juvenile Parkinson's disease [18] [19] [20] [21] [22] [23] [24] and in a variety of human cancers [25] [26] [27] [28] [29] [30] . In studies of inflammation in Parkinson's disease, Parkin knockout (KO) mice display increased susceptibility to inflammation-related degeneration 31 . PARK2 heterozygosity also promotes colon cancer progression in mice with the mutant adenomatous polyposis coli background 27 . However, how Parkin functions as a tumour suppressor, and especially the role of Parkin in inflammation and cancer, remain unclear. Here we found that the AMPK− Parkin axis is a critical regulator of necroptosis and inflammation and that the dysregulation of this pathway contributes to inflammation-associated tumorigenesis.
Results
Parkin KO mice have increased inflammation. To study the physiological functions of Parkin, we used Parkin KO mice. As shown in Fig. 1a ,b, Parkin KO mice at 10 months of age displayed multiple signs of inflammation and initial hyperplasia, such as inflammatory infiltration in the small intestine, weight loss, increased frequency of rectal prolapse, an elevated stool index (stool softness, blood in the stool) and splenomegaly. We hypothesized that increased inflammation due to Parkin deletion leads to tumour initiation or progression. To test our hypothesis, we assessed the levels , Parkin WT and KO mice at 10 months of age were analysed for inflammation by immunohistochemistry (n = 20 mice, small intestine tissues; a) or body weight (n = 25 mice), the incidence of rectal prolapse (pink arrows), stool index (blood content in the stool), splenomegaly (n = 25 mice, three independent experiments) or weight of spleen (n = 5 mice) (b). Representative images from Parkin WT and KO mice (case I and case II, ×40; (i)−(viii), magnification, ×100) (a). c, mRNA levels of the cytokines TNF-α, IL-1β and IL-6 were assessed in the small intestine of Parkin WT and KO mice and MEFs (n = 10; top). Tissue (small intestine) or MEF lysates were subjected to immunoblot as indicated (bottom). y axes, relative mRNA levels of cytokines. d, Representative images of polyps in the small intestine of Parkin WT and KO mice at 12 months (left). Polyp number was determined in the proximal, middle and distal intestine in mice (right). The arrows indicate large adenomatous polyps (adenomas; n = 25). e, The gene expression of Parkin in human ulcerative colitis (ascending and descending colon) tissues. Gene-expression omnibus (GEO) datasets (GE11223) from the NCBI were analysed for Parkin expression. f, Parkin WT and KO MEFs treated with necrotic stimulation (TNF-α (20 ng ml
), cycloheximide (10 μg ml
) and z-VAD (20 μM); T/C/Z) for 4 h and stained with propidium iodide (PI) and 4′,6-diamidino-2-phenylindole (DAPI) for nuclei. The yellow arrows indicate necroptosis; 100 cells were monitored in each experiment. g, The small intestine tissues of Parkin WT and KO mice (n = 3 mice per genotype) at 10 months of age were lysed, and tissue lysates were blotted with the indicated antibodies. The case number is indicated for each lane. Data in c,e are presented as the mean ± s.e.m. Data in b,d,f are presented as the mean ± s.e.m. of three independent experiments. Statistical analysis was performed by one-way analysis of variance (ANOVA; PRISM software). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical source data for b−f are provided in Supplementary Table 1 and unprocessed blots 
Articles

NATuRE CEll BIology
of the inflammatory markers tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 in mouse small intestine and mouse embryonic fibroblasts (MEFs). Levels of these pro-inflammatory cytokines in the Parkin KO groups were significantly higher than those in wild-type (WT) mice (Fig. 1c) . Of the Parkin KO mice, 84% (21 of 25) had 5-10 intestinal polyps at 12 months of age, but none of the 25 WT mice developed polyps (Fig. 1d) . To further investigate the relationship between Parkin and inflammation, we analysed a cohort of ulcerative colitis samples (55 descending, 50 ascending colons) in the uninflamed or inflamed regions from clinically annotated gene-expression datasets 32 for Parkin expression (Fig. 1e) . Within the cohorts, Parkin level was significantly lower in inflamed ascending or descending colon tissues compared with normal or uninflamed tissues. These results suggest that Parkin has an anti-inflammatory function.
Parkin negatively regulates necroptosis by inhibiting RIPK3 activation. We found increased necroptosis, but not apoptosis or autophagy, in Parkin KO MEFs or Parkin-knockdown HT-29 cells under T/C/Z or T/S/Z treatment (TNF-α (T) with cycloheximide (C) or Smac mimetic (S) and the caspase inhibitor z-VAD (Z); Fig. 1f and Supplementary Fig. 1a ). No increased sensitivity to necroptosis was observed in Parkin-knockdown cells under TNF-α alone or T/C treatment. No significant apoptotic event was observed under TNF-α or T/C/Z treatment ( Supplementary Fig. 1b ). We also found that RIPK1/RIPK3 and MLKL phosphorylation were elevated in tissues from Parkin KO mice, but no increase in caspase-3 cleavage, LC3-II or Tom20 was observed (Fig. 1g) . Knockdown of Parkin also increased RIPK3 and MLKL phosphorylation and necroptosis following T/C/Z or T/S/Z treatment in multiple cell lines ( Supplementary Fig. 1c-f) . Collectively, these data indicate that Parkin negatively regulates RIPK3 phosphorylation and thus TNF-α-induced necroptosis.
Parkin interacts with RIPK3 and negatively regulates RIPK1− RIPK3 interaction. We next examined the interaction between Parkin and pronecroptotic factors such as RIPK1 or RIPK3. Endogenous Parkin coimmunoprecipitated with RIPK3, but not RIPK1 or MLKL, after T/C/Z treatment (Fig. 2a,b and Supplementary  Fig. 2a,b) . We also found that the IBR and R2 domains of Parkin were sufficient for RIPK3 interaction ( Fig. 2c and Supplementary  Fig. 2c ). However, an IBR−R2 domain alone did not have any effect on necroptosis/RIPK3 activation (Fig. 2d) . We next generated doxycycline-inducible expression vectors to express Parkin in Parkin KO MEFs. The induction of Parkin resulted in decreased RIPK1− RIPK3 complex formation ( Fig. 2e and Supplementary Fig. 2d ).
To further characterize the Parkin−RIPK3 interaction and identify the regions of RIPK3 that are required for its interaction with Parkin, we expressed Flag-tagged RIPK3 deletion mutants and performed coimmunoprecipitation. The N-terminal domain of RIPK3 is required for its interaction with Parkin, whereas RIPK1 and RIPK3 interaction was mediated through the RHIM domain (Fig. 2f) , suggesting that Parkin does not directly compete with RIPK1 for RIPK3 binding. The phosphorylation of RIPK1/RIPK3 is critical for the formation of a stable RIPK1−RIPK3 pronecroptotic complex. In Parkin KO tissues, RIPK1/RIPK3 phosphorylation was increased (Fig. 1g) , whereas Parkin overexpression inhibited RIPK3 phosphorylation and thus negatively controlled TNF-induced necroptosis in cells (Fig. 2g,h ). Conversely, RIPK1 and RIPK3 protein interaction increased under necroptotic conditions in Parkin KO MEFs ( Supplementary Fig. 2e,f) . These results together suggest that Parkin inhibits RIPK1−RIPK3 complex formation in response to necroptosis signals.
Parkin has been identified as a candidate tumour suppressor and is mutated in several human cancers 28, 29 . We hypothesized that mutations in Parkin might compromise its function in necroptosis and contribute to tumorigenesis. To test this hypothesis, we chose two human colon cancer-derived Parkin mutations, R420H (ref.
28
) and H461R (http://www.cbioportal.org/). Both mutants affect residues located within the IBR−R2 domain, which is the region that binds RIPK3 ( Fig. 2c and Supplementary Fig. 2c ). Both mutations decreased Parkin interaction with RIPK3 ( Fig. 2i ) and failed to suppress RIPK3 phosphorylation or T/C/Z-induced necroptosis compared to WT Parkin (Fig. 2j,k) . As we found that the IBR−R2 domain alone is sufficient to mediate RIPK3 binding, but that it is unable to inhibit necroptosis/RIPK3 activation (Fig. 2c,d ), we hypothesized that Parkin E3 ligase activity is required for the inhibition of RIPK3 activity. We therefore tested ubiquitin ligasedeficient mutants (K161N and T240R Parkin). Both mutant proteins were able to interact with RIPK3 in a similar way to WT Parkin, but were unable to suppress necroptosis (Fig. 2i) . Thus, the E3 ligase activity of Parkin is necessary for its inhibition of necroptosis.
Parkin promotes RIPK3 polyubiquitination. We hypothesized that Parkin regulates the polyubiquitination of RIPK3 following T/C/Z treatment. Indeed, we observed greatly reduced RIPK3 polyubiquitination in Parkin KO MEF cells (Fig. 3a) . Furthermore, overexpression of WT Parkin, but not its catalytically inactive mutant C431S (refs. [22] [23] [24] 29 ), increased polyubiquitination of RIPK3 (but not RIPK1) under necroptotic conditions ( Supplementary Fig. 4a ). The activity of Parkin as a RIPK3-specific E3 ligase to promote RIPK3 ubiquitination in vitro was also validated (Supplementary Fig. 3a ). Table 1 and unprocessed blots for a,b,d−g,i,k are provided in and the Supplementary Fig. 8 . Scale bars, 20 µm (h,j). Dox., doxycycline; HA, human influenza hemagglutinin-tag; IP, immunoprecipitation; n.s., not significant.
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However, the overall RIPK3 protein level was not affected by Parkin expression ( Supplementary Fig. 3b ), suggesting that Parkin associates with RIPK3 and regulates its polyubiquitination but not its stability. We discovered that Parkin mediates K33-linked polyubiquitination of RIPK3 (Fig. 3b-d) . We found that cancer-derived mutations (R420H and H461R) abolished the E3 ligase activity of Parkin (Fig. 3e) . Previous studies showed that puncta-like RIPK3 subcellular localization is important for its function and is indicative of necrosome formation during necroptosis 14, 33 . Therefore, we tested the potential effect of Parkin on the localization of RIPK3 in 
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NATuRE CEll BIology of Tom20 and PLK1, which are two other reported Parkin substrates during mitophagy and mitosis, respectively (Supplementary Fig. 4a ) [22] [23] [24] 29 . Conversely, treatment with carbonyl cyanide m-chlorophenylhydrazone (CCCP), a mitochondrial-uncoupling reagent that activates Parkin during mitophagy [22] [23] [24] , induced Tom20 ubiquitination but not RIPK3 ubiquitination. CCCP treatment also failed to activate RIPK3 ( Supplementary Fig. 4a-g ). We next analysed potential RIPK3 ubiquitination sites from mass spectrometry analysis (http://www.phosphosite.org). Among these, mutations of lysine at the K197, K302 or K364 sites to arginine substantially and then treated with doxycycline and T/C/Z. Cell lysates were then subjected to immunoprecipitation (d) and immunoblotted (e) as indicated. f,g, HT-29 cells depleted of RIPK3 were transfected with the indicated constructs (RIPK3 WT or 3KR) and then treated with doxycycline and T/C/Z for 4 h. The distribution of RIPK3 (red) was detected using immunofluorescence (f) and RIPK3 punctation was quantified (g). In each experiment, 100 cells were monitored. Data in a,c,g are presented as the mean ± s.e.m. of n = 3 independent experiments. Statistical analysis was performed by one-way ANOVA (PRISM). **P < 0.01, ***P < 0.001; statistical source data for a,c,g are provided in Supplementary Table 1 and unprocessed blots 
NATuRE CEll BIology reduced RIPK3 polyubiquitination (Fig. 4a) . As shown in Fig. 4b , mutating all three residues (3KR) largely abolished RIPK3 ubiquitination induced by T/C/Z. Therefore, we predicted that the 3KR mutants would be resistant to Parkin-mediated RIPK3 inhibition. Indeed, we found that Parkin induction decreased necroptosis, RIPK1−RIPK3 interaction, RIPK3 or MLKL phosphorylation and the punctation of RIPK3 in cells expressing WT RIPK3, but had no effect on cells expressing the RIPK3 3KR mutant (Fig. 4c-g ). Collectively, these data indicate that Parkin specifically promotes RIPK3 polyubiquitination under necroptotic conditions to negatively regulate necroptosis.
Parkin is phosphorylated at Ser 9 (S9) by AMPK and activated during necroptosis. Previous studies suggested that Parkin phosphorylation, as well as ubiquitin phosphorylation by PINK1, is necessary for full activation of Parkin's E3 ligase activity. However, we found that PINK1 did not contribute to Parkin activation for RIPK3/ necroptosis inhibition under necroptosis stimuli ( Supplementary  Fig. 4d,e ). Next, we tested whether PINK1-dependent ubiquitin phosphorylation impacts Parkin activity during necroptosis. Ubiquitin-S65 phosphorylation by PINK1 was not involved in Parkin activation during necroptosis ( Supplementary Fig. 5a ). Together, our data suggest that neither ubiquitin-S65 nor PINK1 is involved with Parkin activation during necroptosis.
We previously observed, in a separate project 34 , that AMPK KO cells showed enhanced T/C/Z-induced cell death (Fig. 5a ). Depletion of intracellular ATP is one of the main features of necroptosis 35, 36 . We found that RIPK3 is hyperactivated in AMPK KO cells following T/C/Z treatment, resembling our observation in Parkin KO cells (Fig. 5b and Supplementary Fig. 5b ). Notably, RIPK3 and MLKL phosphorylation reached their peaks 4 h after T/C/Z treatment and then started to decrease, whereas AMPK was found to be slightly phosphorylated at 2 h and its phosphorylation continued to increase steadily up to at least 8 h. Moreover, without RIPK1 or RIPK3, AMPK phosphorylation is prevented, suggesting that AMPK activation under necroptosis is RIPK1 and RIPK3 dependent ( Supplementary Fig. 5c ). AMPK phosphorylation was similar in control and MLKL-deficient cells until 4 h post T/C/Z treatment. However, it significantly decreased at later time points in MLKLdeficient cells (Supplementary Fig. 5d ). This suggests that the initial AMPK activation is RIPK dependent and MLKL activation or low ATP levels during necroptosis may be the main source of the sustained activation of AMPK. The S9 residue on Parkin is predicted to be an AMPK phosphorylation site (http://gps.biocuckoo.cn/) and its surrounding sequence fits with a consensus AMPK phosphorylation motif, LXRXX(pS/pT) ( Supplementary Fig. 5e ,f) 34, 37 . Therefore, we hypothesized that Parkin is a substrate of AMPK. Using an antibody that recognizes AMPK substrates, we confirmed that Parkin is phosphorylated under necroptosis in AMPK-proficient cells but not in AMPK-deficient cells (Fig. 5c) . AMPK itself is also activated under necroptotic conditions ( Fig. 5b and Supplementary Fig. 5g ). Mutating S9 of Parkin to alanine (S9A) impaired not only AMPK phosphorylation, but also its inhibition of RIPK3 phosphorylation (Fig. 5d,e) , suggesting that the phosphorylation of this residue is crucial for Parkin's function in regulating RIPK3. We further confirmed that AMPK could directly phosphorylate Parkin S9 in vitro (Fig. 5f) . Collectively, these results demonstrate that AMPKmediated phosphorylation of Parkin is important for the regulation of the Parkin−RIPK3 pathway during necroptosis. It is worth mentioning that Parkin S9 is highly conserved among vertebrates ( Supplementary Fig. 5f ), suggesting that S9 phosphorylation may have an evolutionarily conserved role in regulating Parkin activity.
Parkin is inactive in unstressed cells. It is possible that S9 phosphorylation activates Parkin E3 ligase activity, in a manner similar to S65 phosphorylation during mitophagy. To confirm the regulation of the Parkin−RIPK3 pathway by AMPK, we examined RIPK3 ubiquitination and observed that T/C/Z-induced RIPK3 ubiquitination was compromised in AMPK KO cells (Fig. 5g) . Ubiquitination of RIPK3 was also abolished by the S9A mutation (Fig. 5h,i and Supplementary Fig. 5j) . Conversely, the S9D mutation, which mimics S9 phosphorylation, dramatically enhanced RIPK3 ubiquitination (Fig. 5h,i and Supplementary Fig. 5h ), consistent with enhanced Parkin E3 ligase activity. However, mutating the PINK1 phosphorylation site on Parkin (S65A) [22] [23] [24] 29 did not affect necroptosis ( Fig. 5d and Supplementary Fig. 5h) . Expression of the Parkin S9D mutant, but not WT or S9A, induced RIPK3 ubiquitination and inhibited necroptosis (Fig. 5i,j) , suggesting that Parkin activation requires AMPK.
AMPK is activated by T/C/Z treatment and its activation is independent of Parkin ( Supplementary Fig. 5i ). In addition, downregulation of Parkin in AMPK KO cells had no further effect on T/C/Z-induced necroptosis (Fig. 5i,j) , suggesting that AMPK and Parkin are epistatic with regard to the regulation of necroptosis. Indeed, treatment with either metformin 38 or phenformin 37 , which trigger metabolic stress and activate AMPK, inhibited RIPK3 and T/C/Z treatment-induced necroptosis in Parkin-proficient cells, but had no effect in Parkin-deficient cells ( Supplementary Fig. 6a-f) . We also found that T/C/Z-induced RIPK3 and MLKL phosphorylation, as well as RIPK3 polyubiquitination, were drastically suppressed by metformin or A-769662, which are indirect and direct AMPK activators, respectively ( Supplementary Fig. 6g,h ). In addition, we confirmed Parkin (S9) phosphorylation following A-769662 treatment ( Supplementary Fig. 6i ). However, AMPK activator alone (without necroptotic stimuli) did not have an impact on RIPK3 phosphorylation and its polyubiquitination ( Supplementary Fig. 6g,h ). Collectively, these data indicate that AMPK-mediated phosphorylation of Parkin at the S9 residue is another mode of Parkin activation that is important for its function in necroptosis.
AMPK−Parkin axis suppresses intestinal inflammation and colitis-associated tumorigenesis in an azoxymethane−dextran sulphate sodium (AOM−DSS) mouse model. We have shown that Parkin ablation contributed to the development of polyps in the small intestine (Fig. 1d) . As Parkin has other cellular functions, such as the regulation of mitophagy, we wanted to address which function of Parkin is important for tumour suppression. We used N- (6-(isopropylsulfonyl) 
quinolin-4-yl)benzo[d]thiazol-5-amine
(GSK'872), a RIPK3 inhibitor 39, 40 , to treat mice to determine whether dysregulated necroptosis in Parkin KO mice contributes to tumorigenesis. GSK'872-treated mice exhibited reduced RIPK3 phosphorylation and intestinal polyps with increased survival (Fig. 6a-e) , suggesting that hyperactivation of RIPK3 and necroptosis are important for tumorigenesis in Parkin KO mice. We confirmed that GSK'872 treatment significantly reduced the punctation of RIPK3 and necroptosis without discernible toxicity in normal mice by measuring body weight and alanine aminotransferase and aspartate aminotransferase levels, as well as by liver histopathological analysis ( Supplementary Fig. 7a-e) . Necroptosis is linked to inflammation 7, 11 and chronic inflammation has been suggested as a high-risk factor for colorectal cancers [8] [9] [10] . Parkin KO mice displayed increased expression of pro-inflammatory cytokines (Figs. 1c and 6e) , while GSK'872 treatment reduced the expression of these cytokines (Fig. 6e) , suggesting that hyperinflammation in Parkin KO mice is due to RIPK3 hyperactivation. Inflammatory bowel disease is a salient example of the link between chronic inflammation and cancer [8] [9] [10] [11] . Therefore, we used the AOM−DSS model of colitis (inflammation)-associated cancer 5, 6 to further study the role of Parkin in inflammation-related tumorigenesis (Fig. 6f-j) . A shortened protocol was adopted to study whether Parkin deficiency accelerates polyp formation. Compared to WT mice, Parkin-deficient mice had increased RIPK3 phosphorylation, higher expression of pro-inflammatory cytokines, a higher number In each experiment, 100 cells were monitored. The yellow arrows indicate necroptosis. c, AMPK WT and KO MEFs were treated with necrotic stimulation for 4 h and cell lysates were then subjected to immunoprecipitation and immunoblotted as indicated. d,e, Parkin KO MEFs were transfected with the indicated constructs (Parkin WT, S9A, S65A, S101A, S136A, S296A, S378A, S384A or S407A (d); WT or S9A (e)) and then treated with necrotic stimulation. Cell lysates were then subjected to immunoprecipitation and immunoblotted as indicated. f, A constitutively active glutathione S-transferase (GST)−AMPK kinase domain (GST−AMPK−CAD (catalytic domain, T172D)) was incubated with the WT or S9A mutant of GST−Parkin in an in vitro kinase assay. The autoradiograph (top) and the Coomassie blue stain (bottom) of the protein bands are shown. g, AMPK WT and KO MEFs were treated with T/C/Z for 4 h. Ubiquitinated proteins were pulled down under denaturing conditions by Ni-NTA agarose and analysed by immunoblotting with the indicated antibodies. h, Cells were transfected with the indicated constructs (WT, S9A or S9D) and then treated with necrotic stimulation. RIPK3 ubiquitination was then examined as before. i,j, AMPK WT and KO MEFs were transfected with the indicated constructs (control shRNA, Parkin shRNA, Parkin WT, S9A or S9D) and then treated with necrotic stimulation for 4 h. RIPK3 ubiquitination (i) and necroptosis (j) were then examined as before. In j, the PI-positive cells are quantified under each condition; 100 cells were monitored in each experiment. Data in a,j are presented as the mean ± s.e.m. of n = 3 independent experiments. Statistical analysis was performed by one-way ANOVA (PRISM). *P < 0.05, **P < 0.01, ***P < 0.001; statistical source data for a,j are provided in Supplementary Table 1 In e and h, y axes indicate relative mRNA levels of cytokines. In b and j, P value for percent survival was calculated using a log-rank test. Kaplan-Meier survival curves of mice are shown. The data in c,e,h−i are presented as the mean ± s.e.m. of n = 3 independent experiments. Statistical analysis was performed by one-way ANOVA (PRISM). *P < 0.05, **P < 0.01, ***P < 0.001; statistical source data for b,c,e,h−j are provided in Supplementary Table 1 and unprocessed blots for d,g are provided in the Supplementary Fig. 8. Scale bars, 1 cm (c,i) .
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of polyps and decreased survival (Fig. 6f-j) . GSK'872 treatment again drastically reduced AOM−DSS-induced RIPK3 phosphorylation, pro-inflammatory cytokine expression and polyp formation (Fig. 6f-i) . As RIPK3 has multiple pro-inflammatory effects independent of necroptosis, we next examined the effect of GW806742X, a MLKL inhibitor, on the AOM−DSS model. GW806742X treatment markedly reduced the expression of pro-inflammatory cytokines and polyp formation in Parkin KO mice ( Supplementary  Fig. 7f ). Taken together, our results suggest a protective role of Parkin against RIPK3-mediated necroptotic inflammation-induced tumorigenesis. Moreover, we found that the AMPK activators metformin and A-769662 also dramatically suppress intestinal polyp growth in AOM−DSS WT mice but have little effect on Parkin KO mice (Fig. 7a-c and Supplementary Fig. 7g-i) . AMPK is activated by metformin in polyps and areas of inflammation (Fig. 7c) . Significantly, in Parkin KO mice, although metformin could also activate AMPK, it did not suppress intestinal polyp growth. These data suggest that AMPK can suppress necroptosis and inflammation-related tumorigenesis by regulating Parkin activation.
Finally, we found a negative correlation between Parkin expression and phosphorylation of RIPK3 in 108 normal human colon tissue and colon cancer tissues and 412 human inflammatory bowel disease (Crohn's disease or ulcerative colitis) patient specimens by immunohistochemical staining (Fig. 7d-f) . These results are consistent with the negative regulation of the phosphorylation of RIPK3 by Parkin in human patient samples.
Discussion
Necroptosis is emerging as a major cellular signal pathway in cancer. In this study, we propose that AMPK and Parkin cooperate to regulate necrosome activation, necroptosis and necroptosis-induced inflammatory tumour formation. Our findings suggest that AMPK is activated under necroptosis-inducing conditions and phosphorylates/activates Parkin, which in turn negatively regulates necroptosis by promoting polyubiquitination (linkage-specific K33) of RIPK3 and the suppression of necrosome formation. Loss of AMPK or Parkin increases the activation of RIPK3 and leads to increased necroptosis, which is a primary source of inflammation (Fig. 7g) .
One surprising finding is that AMPK is activated under necroptotic conditions without any known stimulation, such as starvation or deprivation of glucose. Intracellular ATP levels play a crucial role in the interchange between apoptosis and necrosis. Apoptosis is switched to necroptosis when intracellular ATP levels are depleted [41] [42] [43] [44] . We showed that without RIPK1 or RIPK3, AMPK activation is prevented in necroptosis, suggesting that AMPK is activated in a RIPK1-and RIPK3-dependent manner ( Supplementary  Fig. 5c ). However, AMPK phosphorylation continues to increase even when RIPK1/RIPK3 phosphorylation has started to decline (Supplementary Fig. 5c ). In MLKL-deficient cells, we did not detect any difference in AMPK phosphorylation until later time points (Supplementary Fig. 5d ). Given that activated AMPK, in turn, phosphorylates Parkin to activate Parkin's E3 ligase function, it is possible that the initial AMPK activation is RIPK1-or RIPK3-dependent, in which case low ATP levels during necroptosis may serve as the second activator of AMPK. We suggest that sustained activation of AMPK by RIPK1−RIPK3−MLKL may serve as a negative feedback mechanism to restrain overt necroptosis through Parkin, therefore contributing to the maintenance of cellular homeostasis including an optimal immune response. It will be interesting to dissect how AMPK activation is initiated and sustained in greater detail in future studies.
It was previously reported that PINK1-dependent Parkin phosphorylation (S65) within the Ubl domain activates Parkin E3 ligase activity by inducing a conformational change. AMPK also phosphorylates Parkin at S9 at the N-terminal Ubl domain. This may suggest an activation mechanism of Parkin in which initial phosphorylation at S9 by AMPK leads to disruption of the interaction between the Ubl domain and the C-terminus of Parkin. It has been previously reported that PINK1-induced phosphorylation of ubiquitin at S65 plays a critical role in mediating Parkin activation 24 . However, neither ubiquitin-S65 phosphorylation nor PINK1 was involved in Parkin activation during necroptosis ( Supplementary   Figs. 4d,e and 5a) . Future studies are needed to determine whether ubiquitin itself is modified during necroptosis for Parkin activation
In conclusion, we suggest that the AMPK−Parkin−RIPK3 pathway is a key regulatory mechanism of necroptosis and inflammation-induced tumorigenesis. Our discovery also explains how Parkin loss or mutation contributes to human colon cancer development and therefore reveals a potential target for a therapeutic invention to treat or prevent human colorectal cancer.
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Methods
Mouse strains and MEFs. All animal procedures were approved by the Institutional Animal Care and Use Committee. Mouse strains were described previously 29 .
Parkin KO C57BL/6 (6-8 weeks old, female) mice were purchased from the Jackson Laboratory (Bar Harbor) and mated. Animals were housed in a pathogen-free barrier environment throughout the study. MEFs were isolated from embryonic day 11.5-13.5 (E11.5−E13.5) by uterine dissection for individual embryos. Each embryo was washed softly with 1× PBS (pH 7.2), followed by removal of the mouse embryo's head and liver. The embryo's body was suspended in 0.5 ml 0.25% trypsin− EDTA and then forced through a 1 ml syringe with an 18-gauge needle. The tissue homogenate was incubated for 30 min at 37 °C, triturated by drawing the suspension through a pipette and then evenly divided into two 10 cm tissue culture dishes in Dulbecco's modified Eagle's medium (DMEM) with 15% fetal bovine serum (FBS). Immortalized MEFs were used for all experiments and at least three lines were examined for all studies. AMPK KO MEFs, which have the AMPK-α1 and -α2 genes deleted, were described previously 34 .
Cell culture and reagents. All cell lines were purchased from commercial vendors. Parkin and AMPK KO and WT MEFs were cultured in DMEM (GibcoInvitrogen). Three human colon adenocarcinoma cell lines, HT-29, COLO205 and HCT116, human embryonic kidney 293T cells, human bone osteosarcoma U2OS cells and human epitheloid cervix carcinoma HeLa cells were obtained from the American Type Culture Collection. Cells were cultured in DMEM containing 10% heat-inactivated FBS (Gibco-Invitrogen), sodium bicarbonate (2 mg ml ) and streptomycin (100 μg ml . These constructs have been described previously 20, 21 . HA-tagged Parkin plasmids (empty and WT, S65A, S65D, S378A, S378D, C431A and C431S) were kindly provided by N. Matsuda (Tokyo Metropolitan Institute of Medical Science) and have been described previously 22 . Myc-tagged Parkin constructs (empty and WT, S9A, S9D, S101A, S131A, S136A, S296A, S378A, S384A and S407A) were kindly provided by C. Haass (Ludwig Maximilians University) 19 and some of the mutants were generated by site-directed mutagenesis. The doxycycline-inducible Parkin construct pcDNA6/TR−Parkin was kindly provided by N. Patenge (Centre of Neurology and Hertie Institute for Clinical Brain Research and was described previously 45 . HA-tagged ubiquitin and ubiquitin lysine mutants, such as K6 only, K11 only, K27 only, K29 only, K33 only, K48 only, K63 only, K33R, K48R and K63R were obtained from Addgene. The human Flag-RIPK3 constructs (WT, tetra-Ala RHIM domain (amino acids 459-462) substitution (mutRHIM), K50A, S227A and K50A plus tetra-Ala RHIM domain substitution (K50mutRHIM), K42R, K55R, K62R, K197R, K302R, K364R, K501R and 3KR) constructs were kindly provided by E. S. Mocarski (Emory University School of Medicine) as described previously 46 or were generated by sitedirected mutagenesis. Flag-tagged and HA-tagged mouse RIPK3 vector (Flag, WT and mutants, such as AAAA (mutRHIM), K51A, D143N, T231A/S232A (kinase inactive mutants)) constructs were kindly provided by F. K.-M. Chan and S. Balaji (University of Massachusetts Medical School). The constitutively active GST− AMPK kinase domain (GST−AMPK−CAD, T172D) was kindly provided by Y.-P. Ching (The University of Hong Kong).
Primers and real-time polymerase chain reaction (PCR) with reverse transcription. RNA preparation, cDNA and qRT−PCR were described previously 30 . The following primers were used for real-time quantitative reverse transcription PCR (qRT−PCR).
TNF-α primer sequence: Forward: 5′-CCAGCCAGCAGAAGCTCCCTCAGCGAG-3′ Reverse: 5′-GCGGATCATGCTTTCTGTGCTCATGGTGTC-3′ IL-6 primer sequence: Forward: 5′-CCTGCGTTTAAATAACATCAGCTTTAGCTT-3′ Reverse: 5′-GCACAATGTGACGTCGTTTAGCATCGAA-3′ IL-1β primer sequence: Forward: 5′-CACAGCAGCACATCAACAAG-3′ Reverse: 5′-GTGCTCATGTCCTCATCCTG-3′
Gene silencing by shRNAs, transfection and lentivirus infection. Parkin and PINK1 shRNAs were obtained from Sigma-Aldrich and Open Biosystems (Supplementary Table 3 ). was cloned into a pGEX-4T-1 (Amersham Pharmacia Biotech) vector using the EcoRI−NotI restriction enzyme sites as previously described 6 . BL21 Escherichia coli (Life Technologies) was transformed with the pGEX-4T-1 (GST only and Parkin WT) vectors. Positive E. coli BL21 colonies containing pGEX-4T-1−Parkin were cultured in 3-5 ml LB medium (with ampicillin) at 37 °C overnight, after which the culture was transferred to a fresh 600 ml of LB liquid medium (with ampicillin) for 2-3 h. When the optical density reached a wavelength of 400-600 nm, isopropyl β-d-1-thiogalactopranoside was added with a final concentration of 0.4 M and the culture was shaken at 18 °C overnight. The bacteria were then collected and sonicated on ice in 1× NETN buffer supplemented with the complete protease inhibitor aprotinin. After centrifugation at 5,000g for 10 min at 4 °C, the supernatant was purified using a GST purification resin column (Novagen; Merck KGaA) including aprotinin and PMSF by rocking at 4 °C for 18 h. After washing six times with 1× NETN, GST−Parkin was eluted with GSH elution buffer (30 mM reduced glutathione, 1% Triton X-100, 500 mM Tris−HCl, pH 8.8). The integrity and yield of purified His-tagged fusion proteins as well as commercial RIPK3 recombinant proteins (Novus Biologicals, H00011035-P01) were assessed by SDS PAGE followed by Coomassie blue staining. All His-tagged recombinant proteins were purified using TALON resin (CLONTECH) according to the manufacturer's protocol with minor modifications. Beads were washed three times with 10 ml of PBS buffer (200 mM washing buffer). Proteins were eluted with 300-500 ml of elution buffer (the same as the binding buffer except with 100 mM imidazole). Eluted proteins were concentrated to 1-2 mg ml −1 using a microconcentrator (Filtron). Protein samples were fractionated on 10% SDS polyacrylamide gels and stained by Coomassie brilliant blue G250. Immunohistochemistry. The paraffin sections of human colon cancer tissues and human inflammatory bowel disease patients were obtained from the tissue repository at Kyung Hee University Medical School, Chonnam National University Medical School and Zhujiang Hospital of the Southern Medical University with approval from each of the hospital's internal committees for human tissue use. We affirm that the study is compliant with all relevant ethical regulations regarding research involving existing specimens, with informed consent obtained from all participants. Immunohistochemistry was performed following standard protocols. Briefly, immunohistochemical cytokeratin staining was performed on formalin-fixed, paraffin-embedded tissue using an indirect immunoperoxidase technique. Sections mounted on slides were dewaxed in xylene, dehydrated in ethanol, boiled in 0.01 M citrate buffer (pH 6.0) for 20 min in a microwave oven and then incubated with 3% hydrogen peroxide for 5 min. After washing with PBS, the slides were incubated in 10% normal BSA for 5 min, followed by incubation for 45 min with rabbit polyclonal antibodies recognizing Parkin (ab15954, 1:200) and mouse monoclonal antibody recognizing antiphospho-RIPK3 (Abcam, ab205421, 1:200). After washing, sections were incubated with labelled polymer (Bond Polymer Refine Detection) and diaminobenzidine. The sections were then counterstained with haematoxylin, dehydrated, cleared and mounted.
Statistics and reproducibility. Each assay was performed in triplicate and independently repeated at least three times. The results are presented as mean ± standard error of the mean. Statistical analyses were performed using GraphPad Prism software (version 4.02; GraphPad Software). One-way ANOVA was used for multiple-group comparisons. A difference was considered significant if P < 0.05. Statistical significance was defined as P < 0.05 (*), P < 0.01(**), P < 0.001(***) and P < 0.0001(****). To determine P values for all Kaplan−Meier survival curve analyses, we used the log-rank (Mantel−Cox) test (P = 0.0003, P = 0.0006, P = 0.0061 and P = 0.0014.) 1 nature research | reporting summary The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Data analysis
GraphPad prism (version 6.07) was used to analyze the data. Please refer to methods section for details.
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